Stock CAPR CAPRICOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
5.68 USD +2.34% Intraday chart for Capricor Therapeutics, Inc. -5.18% +16.16%
May. 17 Oppenheimer Initiates Capricor Therapeutics at Outperform Rating MT
May. 13 Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Oppenheimer Initiates Capricor Therapeutics at Outperform Rating
Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024
Capricor: Q1 Earnings Snapshot
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Capricor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
Transcript : Capricor Therapeutics, Inc. - Special Call
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference
Capricor: Q4 Earnings Snapshot
Transcript : Capricor Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CAPR Stock
  4. News Capricor Therapeutics, Inc.
  5. Other languages